Lynx1 Capital Management LP 13D and 13G filings for Allogene Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 09:02 am Purchase |
2024-12-31 | 13G | Allogene Therapeutics, Inc. ALLO |
Lynx1 Capital Management LP | 10,874,723 5.200% |
10,874,723 (New Position) |
Filing |